ATE514091T1 - Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit - Google Patents

Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit

Info

Publication number
ATE514091T1
ATE514091T1 AT08786791T AT08786791T ATE514091T1 AT E514091 T1 ATE514091 T1 AT E514091T1 AT 08786791 T AT08786791 T AT 08786791T AT 08786791 T AT08786791 T AT 08786791T AT E514091 T1 ATE514091 T1 AT E514091T1
Authority
AT
Austria
Prior art keywords
procalcitonin
prognosis
pct
infectious disease
patients
Prior art date
Application number
AT08786791T
Other languages
English (en)
Inventor
Joachim Struck
Andreas Bergmann
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39745280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE514091(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07015271A external-priority patent/EP2020603A1/de
Priority claimed from EP08152651A external-priority patent/EP2101178A1/de
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Application granted granted Critical
Publication of ATE514091T1 publication Critical patent/ATE514091T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT08786791T 2007-08-03 2008-08-01 Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit ATE514091T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07015271A EP2020603A1 (de) 2007-08-03 2007-08-03 Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien
EP08152651A EP2101178A1 (de) 2008-03-12 2008-03-12 Verwendung von Procalcitonin zur Prognose folgender akuter Koronarsyndromen
PCT/EP2008/060176 WO2009019230A2 (en) 2007-08-03 2008-08-01 Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease

Publications (1)

Publication Number Publication Date
ATE514091T1 true ATE514091T1 (de) 2011-07-15

Family

ID=39745280

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10188288T ATE533061T1 (de) 2007-08-03 2008-08-01 Verfahren zur diagnose bakterieller infektionen
AT08786791T ATE514091T1 (de) 2007-08-03 2008-08-01 Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10188288T ATE533061T1 (de) 2007-08-03 2008-08-01 Verfahren zur diagnose bakterieller infektionen

Country Status (9)

Country Link
US (3) US20110136161A1 (de)
EP (4) EP2293078B1 (de)
JP (2) JP5059943B2 (de)
CN (3) CN103123359B (de)
AT (2) ATE533061T1 (de)
DE (1) DE602008021800C5 (de)
ES (3) ES2401703T3 (de)
HK (1) HK1183707A1 (de)
WO (1) WO2009019230A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE533061T1 (de) 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen
CN105334330A (zh) 2009-04-14 2016-02-17 B.R.A.H.M.S有限公司 通过测定降钙素原水平对在原发性非感染性疾病患者中的抗生素治疗进行风险评估
JP5731489B2 (ja) * 2009-06-05 2015-06-10 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸困難を起こした患者における細菌感染の検出
DK2470910T3 (en) 2009-08-28 2017-04-03 Brahms Gmbh Procalcitonin for the prognosis of side effects
ES2601104T3 (es) * 2009-10-13 2017-02-14 B.R.A.H.M.S Gmbh Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio
JP5798133B2 (ja) * 2010-03-08 2015-10-21 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 不特定の愁訴を示す患者における細菌感染及び抗生物質治療の指標を診断するために用いられるプロカルシトニン
ITRM20100121A1 (it) * 2010-03-18 2011-09-19 Univ Pisa Marcatori molecolari per infezioni delle vie urinarie.
WO2011157446A1 (en) * 2010-06-18 2011-12-22 B.R.A.H.M.S Gmbh Biomarkers for the prediction of incident cancer
US20130024205A1 (en) * 2011-07-18 2013-01-24 International Business Machines Corporation Dynamically updating electronic medical records and leveraging a person's path in a facility to mitgate risks
CA2863819C (en) * 2012-02-09 2021-11-23 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
RU2672561C2 (ru) * 2012-04-12 2018-11-16 Б.Р.А.Х.М.С Гмбх Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
ES2709697T3 (es) * 2012-05-18 2019-04-17 Critical Care Diagnostics Inc Procedimientos de tratamiento o predicción del riesgo de un evento de taquiarritmia ventricular
ES2656897T3 (es) * 2012-08-16 2018-02-28 Critical Care Diagnostics, Inc. Procedimientos de predicción del riesgo de desarrollar hipertensión
CN110412265B (zh) * 2012-11-15 2023-04-11 奥索临床诊断有限公司 使用反应时间的校准分析
EP3180621B1 (de) 2014-08-14 2020-04-01 Memed Diagnostics Ltd. Rechnerische analyse biologischer daten mit verteiler und hyperebene
WO2016059636A1 (en) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
JPWO2016199180A1 (ja) * 2015-06-09 2018-04-12 国立大学法人大阪大学 生物学的製剤による関節リウマチの治療効果の予測判定方法
CN108699583B (zh) 2016-03-03 2022-11-01 米密德诊断学有限公司 用于区分细菌和病毒感染的rna决定子
CN106093416B (zh) * 2016-05-18 2018-10-12 北京北方生物技术研究所有限公司 一种一步法检测降钙素原的试剂盒及其制备方法
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
EP3682241B1 (de) * 2017-09-13 2022-03-30 B.R.A.H.M.S GmbH Pct und adm als marker zur überwachung von antibiotikabehandlung
WO2019122088A1 (en) * 2017-12-20 2019-06-27 B.R.A.H.M.S Gmbh Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
WO2022119593A1 (en) * 2020-12-02 2022-06-09 Beckman Coulter, Inc. Detection of probability of developing sepsis
WO2022229444A2 (en) 2021-04-30 2022-11-03 Roche Diagnostics Gmbh Pct marker panels for early detection of sepsis
CN117242350A (zh) 2021-04-30 2023-12-15 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的il6标志物组
WO2022229442A2 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Presepsin marker panels for early detection of sepsis
WO2022229435A2 (en) 2021-04-30 2022-11-03 Roche Diagnostics Gmbh Ngal marker panels for early detection of sepsis
JP2024516681A (ja) 2021-04-30 2024-04-16 エフ． ホフマン－ラ ロシュ アーゲー 敗血症の早期検出のためのｓＦｌｔ１マーカーパネル
JP2024516678A (ja) 2021-04-30 2024-04-16 エフ． ホフマン－ラ ロシュ アーゲー 敗血症の早期検出用のｓｔｒｅｍ１マーカーパネル
CN117203528A (zh) 2021-04-30 2023-12-08 豪夫迈·罗氏有限公司 用于脓毒症的早期检测的gdf15标志物组
US20240219404A1 (en) 2021-04-30 2024-07-04 Roche Diagnostics Operations, Inc. Igfbp7 marker panels for early detection of sepsis
US20240230676A1 (en) 2021-04-30 2024-07-11 Roche Diagnostics Operations, Inc. Esm1 marker panels for early detection of sepsis
EP4409038A1 (de) 2021-09-29 2024-08-07 F. Hoffmann-La Roche AG Mr-proadm-markertafeln zur frühen erkennung von sepsis
WO2023156655A1 (en) 2022-02-21 2023-08-24 F. Hoffmann-La Roche Ag Dll1 marker panels for early detection of sepsis
EP4357778A1 (de) 2022-10-20 2024-04-24 Heraeus Medical GmbH Behandlung von mikrobiellen infektionen mit diagnose durch biomarker d-lactat

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US6147688A (en) 1993-06-28 2000-11-14 Athena Design Systems, Inc. Method and apparatus for defining and selectively repeating unit image cells
US5795725A (en) 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
US6156521A (en) 1997-12-19 2000-12-05 Biosite Diagnostics, Inc. Methods for the recovery and measurement of troponin complexes
US5993811A (en) * 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
DE19903336C2 (de) 1999-01-28 2000-12-14 Brahms Diagnostica Gmbh Gebrauchsfertige Kalibratoren für die Bestimmung von Procalcitonin
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1666881B1 (de) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen
EP1587955A4 (de) 2002-12-24 2007-03-14 Biosite Inc Differenzialdiagnose-marker und verfahren zu ihrer verwendung
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
CA2522709A1 (en) 2003-04-17 2004-11-04 Ciphergen Biosystems, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
WO2005035720A2 (en) * 2003-10-03 2005-04-21 Scantibodies Laboratory, Inc. Methods and use of binding components for improving assay specificity
CA2485722A1 (en) 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
ATE312351T1 (de) 2004-02-13 2005-12-15 Brahms Ag Verfahren zur bestimmung der bildung von endothelinen zu zwecken der medizinischen diagnostik, sowie antikörper und kits für die durchführung eines solchen verfahrens
US20060024744A1 (en) 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
DE102004041659A1 (de) 2004-08-27 2006-03-02 Institut Virion/Serion Gmbh Testvorrichtung für die in vitro Diagnostik von Multianalyt-Tests und deren Verwendung
US20070092911A1 (en) 2005-10-03 2007-04-26 Buechler Kenneth F Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes
CA2612450C (en) 2005-06-28 2014-04-29 Zbx Corporation Membrane array and analytical device
DE102005034174A1 (de) 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
CN1800384A (zh) * 2005-11-08 2006-07-12 浙江大学 降钙素原的制备方法
WO2007103568A2 (en) 2006-03-09 2007-09-13 Biosite, Inc. Methods and compositions for the diagnosis of diseases of the aorta
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
ATE533061T1 (de) * 2007-08-03 2011-11-15 Brahms Gmbh Verfahren zur diagnose bakterieller infektionen
EP2020603A1 (de) 2007-08-03 2009-02-04 BRAHMS Aktiengesellschaft Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien
DE102008037108A1 (de) 2008-08-08 2010-02-11 Samson Aktiengesellschaft System zum Stellen eines Stellorgans
ES2601104T3 (es) * 2009-10-13 2017-02-14 B.R.A.H.M.S Gmbh Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio
US20110263438A1 (en) 2010-04-22 2011-10-27 Mehmet Ali Soylemez Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin

Also Published As

Publication number Publication date
EP2293078B1 (de) 2011-11-09
CN103123359A (zh) 2013-05-29
US20110136161A1 (en) 2011-06-09
WO2009019230A2 (en) 2009-02-12
EP2174143A2 (de) 2010-04-14
WO2009019230A4 (en) 2009-06-25
JP2012237760A (ja) 2012-12-06
HK1183707A1 (en) 2014-01-03
ES2403310T3 (es) 2013-05-17
EP2293076B1 (de) 2012-12-19
DE602008021800C5 (de) 2022-05-05
JP2010536012A (ja) 2010-11-25
EP2301626A2 (de) 2011-03-30
EP2293076A2 (de) 2011-03-09
EP2293078A3 (de) 2011-04-06
CN110346577A (zh) 2019-10-18
JP5185460B2 (ja) 2013-04-17
WO2009019230A3 (en) 2009-04-23
JP5059943B2 (ja) 2012-10-31
EP2293076A3 (de) 2011-03-30
ATE533061T1 (de) 2011-11-15
CN101790687A (zh) 2010-07-28
EP2293078A2 (de) 2011-03-09
EP2301626B1 (de) 2013-01-16
EP2301626A3 (de) 2011-11-16
US20110152170A1 (en) 2011-06-23
ES2401703T3 (es) 2013-04-23
US10456364B2 (en) 2019-10-29
ES2377112T3 (es) 2012-03-22
US20190224135A1 (en) 2019-07-25
CN103123359B (zh) 2015-07-29
EP2174143B1 (de) 2011-06-22
US11241395B2 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
ATE514091T1 (de) Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
ATE554395T1 (de) Diagnose septischer komplikationen
BRPI0816597A2 (pt) "composto, composição farmacêutica, combinação, uso de um composto, método para tratar um indivíduo aflifido com uma consição patológica ou doença e método de modulação de uma atividade um receptor b2 adrenérgico"
DE602005003570D1 (de) Rohr- und universalkupplung für die zufuhr von zahnmedizinischen oder chirurgischen instrumenteen
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
DE602005019694D1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
BR112012000647A8 (pt) "dispositivo de lubrificação implantável e método de tratamento de um paciente humano ou mamífero por meio do dispositivo"
NO20091630L (no) CCR2-antagonister for behandling av fibrose
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
DE602006020850D1 (de) Biomarker zur diagnose einer herzerkrankung sowie verwendung davon
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
WO2010115034A3 (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
BRPI1007637A2 (pt) método para a detecção e/ou a tipificação e/ou a quantificação da presença de um papilomavírus humano (hpv) do tipo 18, 52, 59, 39, 51, 56, 66, 16, 45, 58, 31, 33 e 35 em uma amostra biológica primers e sondas, kit de diagnóstico e uso do kit de diagnóstico
CY1111602T1 (el) ΜΕΘΟΔΟΣ ΓΙΑ ΤΗΝ ΑΝΙΧΝΕΥΣΗ ΤΗΣ ΔΡΑΣΤΙΚΟΤΗΤΑΣ IN VIVO ΤΗΣ ΝΕΥΡΟΤΡΥΨΙΝΗΣ, ΧΡΗΣΗ ΤΗΣ ΜΕΘΟΔΟΥ ΚΑΙ ΧΡΗΣΗ TOY C-ΤΕΡΜΑΤΙΚΟΥ 22-kDa ΘΡΑΥΣΜΑΤΟΣ ΤΗΣ ΑΓΡΙΝΗΣ ΩΣ ΒΙΟΔΕΙΚΤΗ ΕΙΣ ΤΗΝ ΔΙΑΓΝΩΣΗ ΚΑΙ ΠΑΡΑΚΟΛΟΥΘΗΣΗ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΕΧΟΥΝ ΣΧΕΣΗ ΜΕ ΝΕΥΡΟΤΡΥΨΙΝΗ
BR112012000639A8 (pt) "dispositivo de lubrificação implantável e método de tratamento de um paciente humano ou mamífero por meio do dispositivo"
EP2614792A3 (de) Medizinische Membrane, insbesondere zahnmedizinische Membrane sowie Zahnimplantat mit einer solchen Membrane
BRPI0908872A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar, prevenir ou aliviar uma doença ou um distúrbio ou uma condição de um corpo de animal vivo
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina
WO2010123216A3 (ko) Cfh 또는 apoh를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
ES2980597T3 (es) Marcadores útiles en las estrategias de enriquecimiento para el tratamiento de la artrosis
ATE522815T1 (de) Mittel und verfahren zur prognose von nierenversagen bei diabetikern auf basis des plazentalen wachstumsfaktors und löslichem flt-1
BR112013015394A2 (pt) método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto
Tarar et al. ACUTE PANCREATITIS: EVALUATION OF MODIFIED GLASGOW SCORING SYSTEM (IMRIE)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2174143

Country of ref document: EP